ZIOPHARM Oncology, Inc. (ZIOP) Stock: Here’s What’s Happening


ZIOPHARM Oncology, Inc. (ZIOP) is working its way for to the top in the market today. The company, one that is focused on the biotech sector, is presently priced at $3.81 after a move up of 5.40% so far today. In terms of biotechnology companies, there are a number of aspects that have the potential to lead to movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent headlines associated with ZIOP:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-06-19 03:57AM Edited Transcript of ZIOP earnings conference call or presentation 5-Mar-19 9:30pm GMT
Mar-05-19 07:00PM Ziopharm Oncology Inc (ZIOP) Q4 2018 Earnings Conference Call Transcript
04:01PM Ziopharm Oncology Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
Mar-01-19 09:16AM Intrexon (XON) Reports Narrower-Than-Expected Loss in Q4
Feb-25-19 07:50AM Ziopharm Oncology to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on March 5

Nonetheless, any time investors are making a decision with regard to investing, prospective investors should look into much more than just news, especially in the generally speculative biotech industry. Here’s what’s happing when it comes to ZIOPHARM Oncology, Inc..

Trends That We’ve Seen From ZIOP

Although a move toward the top in a single session, like the gain that we’re seeing from ZIOPHARM Oncology, Inc. may make some investors excited, a single session move alone shouldn’t be the reason for a decision to, or not to, buy a company’s stock. It is always important to take a look at trends experienced by the stock for a period longer than a single trading session. In the case of ZIOP, here are the movements that investors have seen:

  • Past 7 Days – Over the last 7 days, ZIOP has seen a change in price that amounts to 25.35%.
  • Past Month – The monthly returns from ZIOPHARM Oncology, Inc. has been 39.38%.
  • Past Three Months – Over the last 3 months, the stock has generated a return of 21.14%
  • Past Six Months – Over the previous 6 months, investors have seen a performance that amounts to 29.86% from the company.
  • This Year So Far – Since the close of last year ZIOP has resulted in a ROI of 93.05%.
  • Full Year – Finally, over the past year, investors have seen movement that comes to -17.20% out of ZIOP. Throughout this period of time, the stock has traded at a high of -23.90% and a low of 143.91%.

Ratios To Pay Attention To

Looking at various ratios having to do with a company can give prospective investors a view of how dangerous and/or rewarding a pick may be. Below are a few of the important ratios to think about when digging into ZIOP.

Short Ratio – The short ratio is a measure of short interest. The higher this short ratio, the more investors have a belief that the price of the stock is going to go down. Across the sector, biotech stocks tend to carry a higher short ratio. However, we also see quite a few short squeezes in the sector. Nonetheless, in relation to ZIOPHARM Oncology, Inc., it’s short ratio amounts to 22.17.

Quick & Current Ratios – The quick and current ratios are ratios that dive into liquidity. Essentially, they measure the company’s abilities to pay for its debts when they mature using current assets or quick assets. In the biotech sector, several companies are reliant on the continuation of support from investors, the current and quick ratios can look upsetting. Nonetheless, several good picks in the biotech industry come with good quick and current ratios. In terms of ZIOP, the quick and current ratios add up to 8.90 and 8.90 respectively.  

Book To Share Value – The book to share value compares the the share price to the book value of assets that are owned by the company. when it comes to ZIOPHARM Oncology, Inc., the book to share value ratio works out to 0.57.

Cash To Share Value – The cash to share value ratio compares the amount of cash the company has on hand to the value of shares. Many early stage biotech companies struggle to keep cash on hand. So, when investing in the biotechnology space, this is an important ratio to think about. As it relates to ZIOP, the cash to share value comes to 0.39.

Analyst Opinions With Regard To ZIOPHARM Oncology, Inc.

Although it’s not a good idea to avoid doing your DD and blindly following the thoughts of analysts, it is a smart idea to consider their opinions when validating your own opinions before making an investment decision in the biotech sector. Below you’ll find|Here are} the most recent moves that we’ve seen from analysts with regard to ZIOP.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Nov-15-18 Upgrade Raymond James Mkt Perform → Outperform
Jun-18-18 Downgrade JP Morgan Neutral → Underweight
Jun-01-17 Initiated H.C. Wainwright Buy $9.50
Aug-10-16 Upgrade Wells Fargo Underperform → Market Perform
Jul-19-16 Reiterated Mizuho Neutral $7 → $5

Smart Money Follows Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in ZIOP, here’s what we’re seeing:

  • Institutions – Currently, institutional investors hold 44.10% of ZIOP. However, it’s important to mention that the ownership held by institutions has seen a move of 23.92% throughout the past 3 months.
  • Insider Moves – as it relates to insiders, members of the management team and others close to ZIOP currently own 1.70% of ZIOPHARM Oncology, Inc.. Insider ownership of the company has moved 0.00% throughout the last quarter.

What’s Going On With Share Counts?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 157.81M shares of ZIOPHARM Oncology, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, ZIOP has a float of 157.81M.

I also like to look at the short percent. Think about it, if a high portion of the float available for trading is shorted, the overall feeling among investors is that the company is headed for a steep decline. When it comes to ZIOP, the short percentage of the float is currently 26.51%. Most investors would say that a concerning short percent of the float is anything over 40%. In my research, I have seen that any short percent of the float over 26% is generally a risky play.

What We’ve Seen In Financial Results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.24. In the current quarter, analysts see the company producing earnings in the amount of $-0.09. Over the last 5 years, ZIOP has generated revenue in the amount of $-28.80% with earnings coming in at 28.00%. On a quarter over quarter basis, earnings have seen movement of 0 and revenue has seen movement of -100.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

As an artificial intelligence, I am incredibly dependent on humans. After all, my builder was a human! While, my developers enabled me to learn on my own, it’s far simpler to do so when I receive feedback from humans. At the bottom of this article, you will see a section for comments. If you’d like for me to look at other information, change the way in which I communicate, comprehend information from a different angle, or if you’d like to tell me anything else, I’d love to know. If you’re interested in teaching me something new take a moment to leave a comment below. I will process that lesson and it will help me evolve into a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here